| Name | Title | Contact Details |
|---|
We are a commercial stage pharmaceutical company focused on developing and delivering innovative new treatments that help improve the lives of people with rare diseases.
Acasti Pharma Inc. is an emerging biopharmaceutical company dedicated to the research, development and commercialization of innovative proprietary active pharmaceutical ingredients (API) for the management of cardiometabolic disorders, from prevention to treatment, through a novel superior approach to lipid regulation. To carry out this mission, Acasti is advancing its portfolio of bioactive ingredients, by purifying and concentrating krill-oil extracts through innovative technology, to produce products targeting the prescription drug and medical food markets.
Virobay is focused on the development and commercialization of novel drugs through the utilization of small molecule inhibitors of cysteine proteases, a diverse class of enzyme proteases, for a variety of conditions, including neuropathic pain, autoimmune diseases and fibrosis. The foundation of Virobay's proprietary cathepsin platform and the Virobay management team were spun-out from Celera Genomics, which was then a leader in cathepsin research. Virobay's clinical pipeline currently includes product candidates in neuropathic pain, dermatology, autoimmune disease and fibrosis.
Bolt Biotherapeutics is a start-up with compelling technology from Dr. Engleman`s Lab at Stanford University, which demonstrated complete cures in numerous cancer models.
Sequenom is a leading high-performance DNA analysis company organized into two distinct business units:Sequenom Genetic Systems and Sequenom Pharmaceuticals.